Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (2): 243-253. doi: 10.19723/j.issn.1671-167X.2023.02.007
Previous Articles Next Articles
Xiao-juan ZHU1,Hong ZHANG1,*(),Shuang ZHANG1,Dong LI1,Xin LI1,Ling XU2,Ting LI1
CLC Number:
1 | Yarden Y . Biology of HER2 and its importance in breast cancer[J]. Oncology, 2001, 61 (Suppl 2): 1- 13. |
2 |
Choong GM , Cullen GD , O'Sullivan CC , et al. Evolving stan-dards of care and new challenges in the management of HER2-positive breast cancer[J]. CA Cancer J Clin, 2020, 70 (5): 355- 374.
doi: 10.3322/caac.21634 |
3 |
Swain SM , Baselga J , Kim SB , et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med, 2015, 372 (8): 724- 734.
doi: 10.1056/NEJMoa1413513 |
4 |
Wolff AC , Hammond ME , Hicks DG , et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Patho-logists clinical practice guideline update[J]. J Clin Oncol, 2013, 31 (31): 3997- 4013.
doi: 10.1200/JCO.2013.50.9984 |
5 |
Gilcrease MZ , Woodward WA , Nicolas MM , et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer[J]. Am J Surg Pathol, 2009, 33 (5): 759- 767.
doi: 10.1097/PAS.0b013e31819437f9 |
6 |
Modi S , Park H , Murthy RK , et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ⅰb study[J]. J Clin Oncol, 2020, 38 (17): 1887- 1896.
doi: 10.1200/JCO.19.02318 |
7 |
Tarantino P , Hamilton E , Tolaney SM , et al. HER2-low breast cancer: Pathological and clinical landscape[J]. J Clin Oncol, 2020, 38 (17): 1951- 1962.
doi: 10.1200/JCO.19.02488 |
8 |
Hammond ME , Hayes DF , Dowsett M , et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28 (16): 2784- 2795.
doi: 10.1200/JCO.2009.25.6529 |
9 |
Schalper KA , Kumar S , Hui P , et al. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: Impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria[J]. Arch Pathol Lab Med, 2014, 138 (2): 213- 219.
doi: 10.5858/arpa.2012-0617-OA |
10 |
Xin L , Wu Q , Zhan C , et al. Multicenter study of the clinico-pathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)[J]. Chin Med J (Engl), 2022, 135 (6): 697- 706.
doi: 10.1097/CM9.0000000000002056 |
11 |
Schettini F , Chic N , Brasó-Maristany F , et al. Clinical, patholo-gical, and PAM50 gene expression features of HER2-low breast cancer[J]. NPJ Breast Cancer, 2021, 7 (1): 1.
doi: 10.1038/s41523-020-00208-2 |
12 |
Denkert C , Seither F , Schneeweiss A , et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22 (8): 1151- 1161.
doi: 10.1016/S1470-2045(21)00301-6 |
13 |
Rossi V , Sarotto I , Maggiorotto F , et al. Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer[J]. Oncologist, 2012, 17 (11): 1418- 1425.
doi: 10.1634/theoncologist.2012-0194 |
14 |
Won HS , Ahn J , Kim Y , et al. Clinical significance of HER2-low expression in early breast cancer: A nationwide study from the Korean Breast Cancer Society[J]. Breast Cancer Res, 2022, 24 (1): 22.
doi: 10.1186/s13058-022-01519-x |
15 |
Horisawa N , Adachi Y , Takatsuka D , et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status[J]. Breast Cancer, 2022, 29 (2): 234- 241.
doi: 10.1007/s12282-021-01303-3 |
16 |
Dehghani M , Keshavarz P , Talei A , et al. The Effects of Low HER2/neu expression on the clinicopathological characteristics of triple-negative breast cancer patients[J]. Asian Pac J Cancer Prev, 2020, 21 (10): 3027- 3032.
doi: 10.31557/APJCP.2020.21.10.3027 |
17 |
Jacot W , Maran-Gonzalez A , Massol O , et al. Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers[J]. Cancers (Basel), 2021, 13 (23): 6059.
doi: 10.3390/cancers13236059 |
[1] | Yu-mei LAI,Zhong-wu LI,Huan LI,Yan WU,Yun-fei SHI,Li-xin ZHOU,Yu-tong LOU,Chuan-liang CUI. Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 262-269. |
[2] | Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282. |
[3] | Qian SU,Xin PENG,Chuan-xiang ZHOU,Guang-yan YU. Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 13-21. |
[4] | Quan ZHANG,Hai-feng SONG,Bing-lei MA,Zhe-nan ZHANG,Chao-hui ZHOU,Ao-lin LI,Jun LIU,Lei LIANG,Shi-yu ZHU,Qian ZHANG. Pre-operative prognostic nutritional index as a predictive factor for prognosis in non-metastatic renal cell carcinoma treated with surgery [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 149-155. |
[5] | Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218. |
[6] | Le-qing CAO,Jing-rui ZHOU,Yu-hong CHEN,Huan CHEN,Wei HAN,Yao CHEN,Yuan-yuan ZHANG,Chen-hua YAN,Yi-fei CHENG,Xiao-dong MO,Hai-xia FU,Ting-ting HAN,Meng LV,Jun KONG,Yu-qian SUN,Yu WANG,Lan-ping XU,Xiao-hui ZHANG,Xiao-jun HUANG. Relationship between treatment and prognosis in patients with late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 1013-1020. |
[7] | Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862. |
[8] | Min QIU,Yan-yan LIAN,Min LU,Bin-shuai WANG,Xiao-jun TIAN,Jian LU,Cheng LIU,Shu-dong ZHANG,Min JIANG,Lu-lin MA. Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 680-685. |
[9] | Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620. |
[10] | Yu-han DENG,Yong JIANG,Zi-yao WANG,Shuang LIU,Yu-xin WANG,Bao-hua LIU. Long short-term memory and Logistic regression for mortality risk prediction of intensive care unit patients with stroke [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 458-467. |
[11] | LAN Lin,HE Yang,AN Jin-gang,ZHANG Yi. Relationship between prognosis and different surgical treatments of zygomatic defects: A retrospective study [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 356-362. |
[12] | WANG Fei,ZHU Xiang,HE Bei,ZHU Hong,SHEN Ning. Spontaneous remission of follicular bronchiolitis with nonspecific interstitial pneumonia: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1196-1200. |
[13] | Wei-bo GAO,Mao-jing SHI,Hai-yan ZHANG,Chun-bo WU,Ji-hong ZHU. Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 921-927. |
[14] | Mei-xiang ZHANG,Wen-zhi SHI,Jian-xin LIU,Chun-jian WANG,Yan LI,Wei WANG,Bin JIANG. Clinical characteristics and prognosis of MLL-AF6 positive patients with acute myeloid leukemia [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 915-920. |
[15] | Yan-fang JIANG,Jian WANG,Yong-jian WANG,Jia LIU,Yin PEI,Xiao-peng LIU,Ying-fang AO,Yong MA. Mid-to-long term clinical outcomes and predictors after anterior cruciate ligament revision [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 857-863. |